# A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

> **NCT03053440** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 201 (actual)

## Conditions studied

- Waldenström's Macroglobulinemia

## Interventions

- **DRUG:** BGB-3111
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03053440
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-25
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053440, "A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03053440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*